Intellia Therapeutics Inc. (NASDAQ:NTLA) shares fell to a low of $57.66 before closing at $59.37. Intraday shares traded counted 1.64 million, which was 8.62% higher than its 30-day average trading volume of 1.79M. NTLA’s previous close was $57.14 while the outstanding shares total 61.29M. The firm has a beta of 2.05. The stock’s Relative Strength Index (RSI) is 47.48, with weekly volatility at 16.92% and ATR at 6.85. The NTLA stock’s 52-week price range has touched low of $9.18 and a $92.00 high. The stock traded higher over the last trading session, gaining 3.90% on 03/10/21.
Investors have identified the Biotechnology company Intellia Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $4.22 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Intellia Therapeutics Inc. (NTLA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 616.52 million total, with 64.25 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -3.01 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NTLA sounds very interesting.
Is the stock of NTLA attractive?
In related news, Director, FORMELA JEAN FRANCOIS sold 501,945 shares of the company’s stock in a transaction that recorded on Feb 26. The sale was performed at an average price of 60.29, for a total value of 30,262,716. As the sale deal closes, the President and CEO, LEONARD JOHN M now sold 28,043 shares of the company’s stock, valued at 2,103,225. Also, EVP, General Counsel, Rivera Jose E sold 11,489 shares of the company’s stock in a deal that was recorded on Feb 09. The shares were price at an average price of 75.00 per share, with a total market value of 861,675. Following this completion of acquisition, the President and CEO, LEONARD JOHN M now holds 22,942 shares of the company’s stock, valued at 1,552,185. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.20%.
9 out of 15 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on Intellia Therapeutics Inc.. 0 analysts has assigned a Sell rating on the NTLA stock. The 12-month mean consensus price target for the company’s shares has been set at $78.46.